# REGENERON PHARMACEUTICALS, INC. (REGN) FY2026 Q1 P&L / Income Statement

- Company: REGENERON PHARMACEUTICALS, INC. (REGN)
- Period: 2026-01-01 to 2026-03-31
- Filing: Q1 FY2026 10-Q, filed 2026-04-29, accession number 0000872589-26-000016
- Page: https://plicit.ai/financials/regn/fy2026-q1-income-statement
- Chart image: https://plicit.ai/charts/regn-fy2026-q1-income-statement-sankey.png

## Chart details: Revenue by Product and Service by Geography

Income statement for 2026-01-01 through 2026-03-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 3,605,400,000 US dollars
- **Cost of revenue (calculated)**: 669,400,000 US dollars
- **Gross profit (calculated)**: 2,936,000,000 US dollars
- **Operating expenses (calculated)**: 2,293,100,000 US dollars
- **Income from operations**: 642,900,000 US dollars
- **Total other income (expense)**: 188,300,000 US dollars
- **Income before income taxes**: 831,200,000 US dollars
- **Income tax expense**: 104,000,000 US dollars
- **Net income**: 727,200,000 US dollars
- **Lynozyfic**: 11,200,000 US dollars
- **Other products**: 31,300,000 US dollars
- **EYLEA HD And EYLEA - UNITED STATES**: 941,500,000 US dollars
- **EYLEA HD - UNITED STATES**: 468,400,000 US dollars
- **Evkeeza - UNITED STATES**: 45,700,000 US dollars
- **EYLEA Net Product Sales - UNITED STATES**: 473,100,000 US dollars
- **Libtayo - UNITED STATES**: 286,100,000 US dollars
- **Libtayo - Rest Of World**: 152,100,000 US dollars
- **Praluent - UNITED STATES**: 66,600,000 US dollars
- **Undisclosed (calculated)**: 1,129,400,000 US dollars
- **Cost of goods sold, collaboration and contract manufacturing**: 669,400,000 US dollars
- **Research and development**: 1,543,500,000 US dollars
- **Acquired in-process research and development**: 101,900,000 US dollars
- **Selling, general, and administrative**: 647,700,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service

- Page: https://plicit.ai/financials/regn/fy2026-q1-income-statement/revenue-by-product-and-service
- Chart image: https://plicit.ai/charts/regn-fy2026-q1-revenue-by-product-and-service-sankey.png

Income statement for 2026-01-01 through 2026-03-31. View: Product and service (Schedule of Net Product Sales). Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 3,605,400,000 US dollars
- **Cost of revenue (calculated)**: 669,400,000 US dollars
- **Gross profit (calculated)**: 2,936,000,000 US dollars
- **Operating expenses (calculated)**: 2,293,100,000 US dollars
- **Income from operations**: 642,900,000 US dollars
- **Total other income (expense)**: 188,300,000 US dollars
- **Income before income taxes**: 831,200,000 US dollars
- **Income tax expense**: 104,000,000 US dollars
- **Net income**: 727,200,000 US dollars
- **Libtayo**: 438,200,000 US dollars
- **Other products**: 31,300,000 US dollars
- **Lynozyfic**: 11,200,000 US dollars
- **Undisclosed (calculated)**: 3,124,700,000 US dollars
- **Cost of goods sold, collaboration and contract manufacturing**: 669,400,000 US dollars
- **Research and development**: 1,543,500,000 US dollars
- **Acquired in-process research and development**: 101,900,000 US dollars
- **Selling, general, and administrative**: 647,700,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.

## Chart details: Revenue by Product and Service (2)

- Page: https://plicit.ai/financials/regn/fy2026-q1-income-statement/revenue-by-product-and-service-2
- Chart image: https://plicit.ai/charts/regn-fy2026-q1-revenue-by-product-and-service-2-sankey.png

Income statement for 2026-01-01 through 2026-03-31. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Revenues**: 3,605,400,000 US dollars
- **Cost of revenue (calculated)**: 669,400,000 US dollars
- **Gross profit (calculated)**: 2,936,000,000 US dollars
- **Operating expenses (calculated)**: 2,293,100,000 US dollars
- **Income from operations**: 642,900,000 US dollars
- **Total other income (expense)**: 188,300,000 US dollars
- **Income before income taxes**: 831,200,000 US dollars
- **Income tax expense**: 104,000,000 US dollars
- **Net income**: 727,200,000 US dollars
- **Net product sales**: 1,534,500,000 US dollars
- **Collaboration revenue**: 1,899,700,000 US dollars
- **Other revenue**: 171,200,000 US dollars
- **Cost of goods sold, collaboration and contract manufacturing**: 669,400,000 US dollars
- **Research and development**: 1,543,500,000 US dollars
- **Acquired in-process research and development**: 101,900,000 US dollars
- **Selling, general, and administrative**: 647,700,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.